These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 31827241)

  • 41. Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.
    Barlaam B; Casella R; Cidado J; Cook C; De Savi C; Dishington A; Donald CS; Drew L; Ferguson AD; Ferguson D; Glossop S; Grebe T; Gu C; Hande S; Hawkins J; Hird AW; Holmes J; Horstick J; Jiang Y; Lamb ML; McGuire TM; Moore JE; O'Connell N; Pike A; Pike KG; Proia T; Roberts B; San Martin M; Sarkar U; Shao W; Stead D; Sumner N; Thakur K; Vasbinder MM; Varnes JG; Wang J; Wang L; Wu D; Wu L; Yang B; Yao T
    J Med Chem; 2020 Dec; 63(24):15564-15590. PubMed ID: 33306391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML.
    O' Reilly E; Dhami SPS; Baev DV; Ortutay C; Halpin-McCormick A; Morrell R; Santocanale C; Samali A; Quinn J; O'Dwyer ME; Szegezdi E
    Sci Rep; 2018 Oct; 8(1):15752. PubMed ID: 30361682
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.
    Lyle L; Daver N
    Am J Manag Care; 2018 Aug; 24(16 Suppl):S356-S365. PubMed ID: 30132679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy.
    Liu J; Li S; Wang Q; Feng Y; Xing H; Yang X; Guo Y; Guo Y; Sun H; Liu X; Yang S; Mei Z; Zhu Y; Cheng Z; Chen S; Xu M; Zhang W; Wan N; Wang J; Ma Y; Zhang S; Luan X; Xu A; Li L; Wang H; Yang X; Hong Y; Xue H; Yuan X; Hu N; Song X; Wang Z; Liu X; Wang L; Liu Y
    Blood; 2024 May; 143(18):1825-1836. PubMed ID: 38211332
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
    Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
    Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
    Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
    Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
    Bate-Eya LT; den Hartog IJ; van der Ploeg I; Schild L; Koster J; Santo EE; Westerhout EM; Versteeg R; Caron HN; Molenaar JJ; Dolman ME
    Oncotarget; 2016 May; 7(19):27946-58. PubMed ID: 27056887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells.
    Wang Q; Wan J; Zhang W; Hao S
    Leuk Lymphoma; 2019 Sep; 60(9):2170-2180. PubMed ID: 30626241
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
    Tanos R; Karmali D; Nalluri S; Goldsmith KC
    BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
    Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
    Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
    Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
    Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
    Choudhary GS; Tat TT; Misra S; Hill BT; Smith MR; Almasan A; Mazumder S
    Oncotarget; 2015 Jul; 6(19):16912-25. PubMed ID: 26219338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
    Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J
    Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CDK9 inhibition as an effective therapy for small cell lung cancer.
    Valdez Capuccino L; Kleitke T; Szokol B; Svajda L; Martin F; Bonechi F; Krekó M; Azami S; Montinaro A; Wang Y; Nikolov V; Kaiser L; Bonasera D; Saggau J; Scholz T; Schmitt A; Beleggia F; Reinhardt HC; George J; Liccardi G; Walczak H; Tóvári J; Brägelmann J; Montero J; Sos ML; Őrfi L; Peltzer N
    Cell Death Dis; 2024 May; 15(5):345. PubMed ID: 38769311
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies.
    Fischer MA; Friedlander SY; Arrate MP; Chang H; Gorska AE; Fuller LD; Ramsey HE; Kashyap T; Argueta C; Debler S; Byrne M; Villaume MT; Shaver AC; Senapedis W; Landesman Y; Baloglu E; Shacham S; Savona MR
    Blood Adv; 2020 Feb; 4(3):586-598. PubMed ID: 32045477
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CDK9 inhibitors in multiple myeloma: a review of progress and perspectives.
    Borowczak J; Szczerbowski K; Ahmadi N; Szylberg Ł
    Med Oncol; 2022 Jan; 39(4):39. PubMed ID: 35092513
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combining T-cell-based immunotherapy with venetoclax elicits synergistic cytotoxicity to B-cell lines in vitro.
    Murakami S; Suzuki S; Hanamura I; Yoshikawa K; Ueda R; Seto M; Takami A
    Hematol Oncol; 2020 Dec; 38(5):705-714. PubMed ID: 32822067
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Venetoclax: Targeting BCL2 in Hematological Cancers.
    Scheffold A; Jebaraj BMC; Stilgenbauer S
    Recent Results Cancer Res; 2018; 212():215-242. PubMed ID: 30069633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
    Natoni A; Murillo LS; Kliszczak AE; Catherwood MA; Montagnoli A; Samali A; O'Dwyer M; Santocanale C
    Mol Cancer Ther; 2011 Sep; 10(9):1624-34. PubMed ID: 21768328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.